Immunovia carried out the study with an undisclosed global pharma company and found that its IMMray could differentiate healthy controls from NSCLC samples with a 95% accuracy.
The company stated that NSCLC is considered to account for about 14% of all new cancers and it is one of the top three cancer types by incidence and number one by mortality.
The study included 100 serum samples, 50 NSCLC and 50 controls and was performed to assess the technical performance of the IMMray platform in lung cancer.
The companies now plan to continue the collaboration with further larger studies to confirm the preliminary findings.
Immunovia CEO Mats Grahn said “Since IMMray has previously demonstrated similar high (98%) accuracy in detecting pancreatic cancer, the results from this study strengthen our belief that IMMray has the potential to become a standard common platform for cancer diagnosis based on blood samples, and we are very much looking forward to the next steps of this collaboration.”
Investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden, founded Immunovia in 2007.
The company aims to to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases including cancer, more accurately and earlier than it was previously possible.
The company’s core technology platform, IMMray, is based on antibody biomarker microarray analysis.
Presently, clinical validation studies are being conducted for the commercialization of IMMray PanCan-d. This could be the first blood based test for early diagnosis of pancreatic cancer.
In 2016, the company started the program focused on autoimmune diseases diagnosis prognosis and therapy monitoring.
The first test from the program, IMMray SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation.
